Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2019-05-31

FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)

View source ↗

Summary

The FDA approved a supplemental application for SABRIL (vigabatrin) submitted by Lundbeck Pharmaceuticals LLC, resulting in a labeling change. The action update…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SABRIL (VIGABATRIN)

Snippet

SUPPL AP for SABRIL (VIGABATRIN)